Literature DB >> 30844951

Herpes Zoster Ophthalmicus Review and Prevention.

Andrew R Davis1, John Sheppard.   

Abstract

Varicella-zoster virus (VZV) is the etiologic agent of both chickenpox and Herpes zoster (HZ). In the United States, there are around one million cases of HZ per year. Ten percent of HZ cases are subtyped as herpes zoster ophthalmicus (HZO) specifically and involve the V1 distribution. Herpes zoster ophthalmicus is a significant cause of blindness in the United States. This article will provide a basic overview of VZV, HZ, and HZO with a focus on preventative measures in an effort to prevent blindness through improving clinician awareness and education. The differences in clinical effectiveness and duration of effectiveness of the live (Zostavax) and recombinant vaccines (Shingrix) are illustrated. There is now a trend toward using the recombinant vaccine as recommended by the Advisory Committee for Immunization Practices (ACIP) for healthy adults 50 or older.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30844951     DOI: 10.1097/ICL.0000000000000591

Source DB:  PubMed          Journal:  Eye Contact Lens        ISSN: 1542-2321            Impact factor:   2.018


  6 in total

1.  Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study.

Authors:  Yuwei Sun; Eric Kim; Christina L Kong; Benjamin F Arnold; Travis C Porco; Nisha R Acharya
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

Review 2.  Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411

Review 3.  Herpes zoster: A Review of Clinical Manifestations and Management.

Authors:  Anant Patil; Mohamad Goldust; Uwe Wollina
Journal:  Viruses       Date:  2022-01-19       Impact factor: 5.048

Review 4.  Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review.

Authors:  Rosanna Dammacco; Silvana Guerriero; Giovanni Alessio; Franco Dammacco
Journal:  Int Ophthalmol       Date:  2021-11-21       Impact factor: 2.029

5.  A case of herpes zoster ophthalmicus after third dose of Comirnaty (BNT162b2 mRNA) vaccine.

Authors:  Fabrizio Martora; Gabriella Fabbrocini; Vincenzo Picone
Journal:  Dermatol Ther       Date:  2022-03-04       Impact factor: 3.858

6.  Locked-nucleotide antagonists to varicella zoster virus small non-coding RNA block viral growth and have potential as an anti-viral therapy.

Authors:  Biswajit Das; Punam Bisht; Paul R Kinchington; Ronald S Goldstein
Journal:  Antiviral Res       Date:  2021-07-22       Impact factor: 10.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.